Sudeep Pharma Ltd.

808.45+8.2 (+1.02%)

9 Jul, 3:29 PM

Income Statement

Abridged

Understanding Income Statement

Sudeep Pharma Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M PRESS
Total Revenue	343.01	426.17	454.67	497.41	642.26
Cost of Operating Revenue	149.10	208.59	188.48	190.86	242.12
Gross Profit	193.91	217.58	266.19	306.55	400.14
Gross Margin	56.5	51.1	58.5	61.6	62.3
Total Operating Expenses	280.55	347.45	285.89	321.25	435.16
Operating Profit	62.46	78.72	168.78	176.16	207.09
Operating Margin	18.2	18.5	37.1	35.4	32.2
Financing Income/(Expense) - Net	3.76	3.56	1.15	2.27	-7.60
Profit before Taxes	68.53	85.98	174.82	182.85	228.07
Income Taxes	18.74	23.66	41.67	44.12	53.79
Profit after Tax	49.80	62.32	133.15	138.73	172.89
PAT Margin	14.5	14.6	29.3	27.9	26.9
EPS - Basic - ex Extraordinary Items	4.41	5.52	11.79	12.28	15.50
EPS - Diluted - ex Extraordinary Items	4.41	5.52	11.79	12.28	15.50
EBIT	62.46	78.72	168.78	176.16	207.09
EBITDA	67.16	86.64	177.79	186.75	221.90
EBITDA Margin	19.6	20.3	39.1	37.5	34.6

Balance Sheet

Abridged

Understanding Balance Sheet

Sudeep Pharma Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	PR	PR	PR	AR	PRESS
Total Current Assets	196	230	275	424	624
Long-Term Investments	0	0	0	0	19
Property Plant & Equipment - Net	146	184	225	277	447
Total Non-Current Assets	149	190	239	293	551
Total Assets	345	420	514	717	1,175
Total Current Liabilities	148	171	137	175	202
Long Term Debt	29	20	13	41	36
Total Non-Current Liabilities	35	26	21	49	75
Total Liabilities	182	197	158	224	277
Total Shareholders' Equity	163	223	356	493	883
Minority Interest	-	-	-	-	15
Total Equity	163	223	356	493	898
Total Liabilities & Equity	345	420	514	717	1,175

Cash Flow

Abridged

Understanding Cash Flow Statement

Sudeep Pharma Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	56.85	81.56	143.66	157.88	185.00
Working Capital - Increase/(Decrease)	-59.41	-33.07	-77.85	-109.02	-112.07
Net CF from Operating Activities	-2.57	48.49	65.81	48.86	72.93
Capital Expenditures - Net	57.72	47.11	52.40	63.89	118.15
Net CF from Investing Activities	-38.49	-50.11	-49.40	-78.89	-334.31
Stock - Issuance/(Retirement) - Net	-	-	-	-	248.34
Debt - LT & ST - Issuance/(Retirement) - Total	52.39	-5.13	-8.97	58.12	10.29
Net Cash Flow from Financing Activities	50.57	-9.78	-12.73	52.70	247.29
Free Cash Flow to Equity	-7.89	-3.75	4.43	43.09	-34.92
Free Operating CF net dividend	-60.32	1.34	13.34	-15.37	-45.22
Free Operating CF	-60.32	1.34	13.34	-15.37	-45.22

Business Segment Analysis

FY End:

Mar 25

Sudeep Pharma Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Revenue / Sales

Pharmaceutical, food and nutrition (65.8%)₹ 330.50 CrSpecialty ingredients (34.2%)₹ 171.50 Cr

Assets

Pharmaceutical, food and nutrition (70.1%)₹ 502.63 CrSpecialty ingredients (29.6%)₹ 212.15 CrUnallocated (0.3%)₹ 2.39 Cr

Regional Segment Analysis

FY End:

Mar 25

Sudeep Pharma Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (40.7%)₹ 204.45 CrOthers (40.3%)₹ 202.36 CrUSA (19.0%)₹ 95.18 Cr

Historical Segment Analysis

Track how Sudeep Pharma Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Sales

Assets

Business

Regional

Business

We don't have enough data to show the Capex for Sudeep Pharma Ltd..

Frequently Asked Questions

What is the revenue of Sudeep Pharma Ltd.?

The latest trailing twelve month revenue of Sudeep Pharma Ltd. is ₹ 642.26 Cr, reflecting a 1-year growth of 29.12% and a 3-year CAGR of 14.65%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Sudeep Pharma Ltd.?

The latest trailing twelve month net profit (PAT) of Sudeep Pharma Ltd. is ₹ 172.89 Cr, with a 3-year earnings CAGR of 41.10%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Sudeep Pharma Ltd.?

The trailing twelve month EBITDA of Sudeep Pharma Ltd. is approximately ₹ 207.09 Cr (based on an operating margin of 32.24%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Sudeep Pharma Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Sudeep Pharma Ltd. is 15.50. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Sudeep Pharma Ltd.?

The debt-to-equity ratio of Sudeep Pharma Ltd. stands at 0.17. The interest coverage ratio is 27.23x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Sudeep Pharma Ltd.?

The estimated book value per share of Sudeep Pharma Ltd. is 79.00 (derived from a P/B ratio of 10.23 and market price of ₹ 808.45), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Sudeep Pharma Ltd.?

The trailing twelve month operating cash flow of Sudeep Pharma Ltd. is ₹ 72.93 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Sudeep Pharma Ltd. report consolidated or standalone financials?

Sudeep Pharma Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.